Related by context. All words. (Click for frequent words.) 73 preclinical efficacy 71 potent antitumor activity 69 ENMD # 68 oral bioavailability 67 delafloxacin 67 Carfilzomib 67 antiviral efficacy 67 xenograft models 66 antiviral activity 66 antitumor efficacy 66 CGEN # 66 antitumor activity 66 bactericidal activity 65 oral prodrug 65 neuroprotective properties 65 RGB # 65 preclinical studies 65 radezolid 65 GLYX 65 PEG SN# 64 XL# inhibits 64 huC# DM4 64 OMP #M# 64 preclinically 64 cMET 64 depsipeptide 64 Preclinical studies 64 preclinical models 64 Sym# 64 antitumor 64 antiangiogenic activity 64 ganetespib 64 demonstrated antitumor activity 64 favorable pharmacokinetic profile 64 OXi# 64 retapamulin 64 DXL# 64 telomerase inhibitor drug 63 CRLX# 63 ZFN modified 63 anti CD3 63 preclinical 63 vidofludimus 63 ON #.Na 63 Onconase 63 anticancer activity 63 antitumor effects 63 solithromycin 63 biodistribution 63 investigational humanized monoclonal antibody 63 Tß4 63 BAL# [001] 63 fosbretabulin 63 Valortim 63 vivo validation 63 pharmacodynamic profile 63 potently inhibited 62 pharmacokinetic properties 62 GRN#L 62 huN# DM1 62 antiviral potency 62 MCSP respectively 62 CCX# 62 PRT# 62 INGN 62 novel peptide 62 Valortim R 62 CYT# 62 antisense inhibition 62 potent inhibition 62 ESBA# 62 HGS ETR2 62 novel histone deacetylase 62 Traficet EN 62 Lpathomab 62 ocular formulation 62 telomerase inhibitor 62 nonclinical studies 62 nanoviricides 62 pharmacodynamic properties 62 CCR9 antagonist 62 hemagglutination inhibition HAI 62 trodusquemine 62 Anticalin ® 62 CD# CEA 62 vivo potency 62 NS#/#A protease 62 vivo 62 antisense inhibitors 62 vitro studies 62 NEUGENE 62 Multimeric 62 Zalypsis 62 rBChE 62 pan HDAC inhibitor 62 Aplidin 62 AAG geldanamycin analog 62 phosphatidylserine PS targeting 62 Phase 2a trial 62 MEK inhibitors 62 systemically administered 62 NEUGENE antisense 62 vascular disrupting agent 62 CCR9 61 Azedra 61 vitro potency 61 targeting CD# 61 EGFR HER2 61 Darinaparsin 61 tumor xenograft models 61 Preclinical studies suggest 61 vitro experiments 61 angiotensin analog 61 pharmacodynamic PD 61 S/GSK# 61 Interferon alpha 61 mitogen activated ERK kinase 61 anti amnesic 61 iroxanadine 61 Archexin 61 Pharmacokinetics PK 61 GLP toxicology studies 61 imatinib Gleevec ® 61 Tarvacin TM 61 Omacetaxine 61 nucleotide analog 61 HCV protease 61 Thiovir 61 PXD# 61 Phase 1a clinical 61 INCB# [001] 61 Zybrestat 61 selective kinase inhibitor 61 Phase Ib clinical 61 Valortim ® 61 safety tolerability pharmacokinetic 61 GMX# 61 TLR8 agonist 61 APOPTONE 61 GAP #B# 61 Symadex 61 PCK# 61 Sphingomab 61 tolerability profile 61 NEUGENE R 61 #ME# 61 pharmacokinetic PK study 61 immune modulating 61 CDK inhibitor 61 orally administered inhibitor 61 PSN# [002] 61 TG# [003] 61 mertansine 61 UsiRNAs 61 hematological tumors 61 R#/MEM # 61 CBLC# 61 IL #E 61 Phase 1b clinical trials 61 viral kinetics 60 ongoing Phase 1b 60 Spiegelmer ® 60 splice variants 60 immune stimulatory 60 H#N# VLP vaccine 60 Factor VIIa 60 protein kinase inhibitor 60 CG# [003] 60 CLORETAZINE TM VNP#M 60 mouse xenograft models 60 HGS ETR1 mapatumumab 60 JAK1 60 histone deacetylase inhibitor 60 oral JAK1 60 S1P antibody 60 isotypes 60 Zysolin TM 60 Enzastaurin 60 REP# 60 XOMA 3AB 60 MEK inhibitor 60 PI3K/mTOR 60 vivo preclinical 60 kinase inhibition 60 telomerase therapeutic 60 HQK 60 potently inhibit 60 tubulin inhibitor 60 inhibitory activity 60 immunological responses 60 Solazed TM 60 HuMax EGFr 60 antiproliferative effects 60 Vaxfectin R adjuvant 60 SCH # 60 Apoptone 60 DiLA2 liposomes 60 Kinase Inhibitor 60 tolerability profiles 60 CTAP# Capsules 60 BNC# 60 Nanobody ® 60 monoclonal antibody mAb 60 CORT # 60 experimental autoimmune encephalomyelitis 60 A3 adenosine receptor 60 pharmacokinetic PK 60 receptor tyrosine kinase inhibitor 60 p# inhibitor 60 PI3 kinase inhibitors 60 JAK inhibitor 60 Xanafide 60 liposomal formulation 60 therapeutic monoclonal antibody 60 SinuNase ™ 60 Protectan CBLB# 60 HGS# 60 novel VDA molecule 60 PI3K inhibitor 60 tumorigenicity 60 TRIOLEX 60 Aurora kinase 59 Exelixis compounds 59 pharmacodynamic profiles 59 Presents Preclinical Data 59 BRAF inhibitor 59 Preclinical Study 59 anti leukemic 59 Virulizin ® 59 ALN TTR# 59 TLR8 59 DiLA2 59 TRO# 59 highly selective inhibitor 59 neuroprotective effects 59 AEG# 59 histone deacetylase HDAC inhibitor 59 Azedra TM 59 CD# expressing 59 AACR NCI EORTC 59 Phase Ib study 59 reversible inhibitor 59 AZX# 59 immunogenicity 59 inhibitory effects 59 cytotoxicity 59 BAL# [002] 59 novel anticancer 59 anti proliferative 59 adecatumumab MT# 59 small molecule defensin 59 vivo experiments 59 GRNVAC1 59 NP2 Enkephalin 59 Catena ® 59 CYT# potent vascular disrupting 59 Cloretazine R 59 IMA# 59 RNA antagonist 59 ALN TTR 59 tumor xenografts 59 angiogenesis inhibitor 59 OncoVEX GM CSF 59 isoform selective 59 XmAb# 59 proteasome inhibitor 59 evaluating tivozanib 59 ANAVEX #-# [001] 59 NXL# 59 compound AEZS 59 MetMAb 59 CA4P 59 JAK inhibitors 59 xenograft 59 Kahalalide F 59 Vaxfectin R 59 efficacy 59 anti angiogenic agent 59 generation nucleoside analog 59 mouse xenograft 59 IRX 2 59 immune modulatory 59 PRTX 59 tumor regression 59 MVA BN R 59 delta isoform 59 PSMA ADC 59 obatoclax 59 Monoclonal Antibody 59 virus HCV protease inhibitor 59 selective agonist 59 LymphoStat B TM 59 vitro cytotoxicity 59 syngeneic 59 peptide conjugated 59 alpha#beta# integrin 59 Phase Ib II 59 orally bioavailable 59 milatuzumab 59 SAR# [004] 59 HGS ETR1 59 cannabinor 59 pathophysiological effects 59 PEGPH# 59 favorable tolerability 59 MEK inhibitor RDEA# 59 candidate CRLX# 59 #th Annual Interscience 59 Panzem R 59 HCV protease inhibitor 59 DermaVir Patch 59 pDNA vaccines 59 immunomodulation 59 alvespimycin 59 antiproliferative activity 59 Belerofon 59 anti fibrotic 59 pharmacokinetics PK 59 adenoviral 59 Hsp# Inhibitor 58 Curaxin CBLC# 58 humanized monoclonal antibodies 58 Serdaxin 58 multi kinase inhibitor 58 Reports Preclinical Data 58 Guanilib 58 davunetide intranasal AL 58 vascular disrupting agents 58 PKC# 58 IAP inhibitor 58 influenza VLP vaccine 58 Anticalin R 58 pharmacokinetic parameters 58 pharmacodynamic 58 OncoVEX 58 AS# amonafide L malate 58 indibulin 58 GVAX ® 58 metaglidasen 58 non nucleoside inhibitor 58 MLN# 58 Prodarsan R 58 axitinib 58 iSONEP 58 DASISION 58 p# alpha [001] 58 immune modulation 58 pharmacokinetic profiles 58 mechanistic insights 58 MAb 58 phase IIa clinical 58 pharmacodynamic markers 58 OncoVex 58 HCV protease inhibitors 58 Tarceva TM 58 Phase Ib clinical trials 58 HDAC Inhibitor 58 QLT# 58 mGluR5 negative 58 antisense inhibitor 58 rxRNA 58 Azixa 58 siRNAs targeting 58 JAK2 inhibitor 58 aurora kinase 58 HIV integrase inhibitors 58 TLR7 58 Eg5 58 HSP# inhibitor 58 DermaVir 58 GLPG# 58 Romidepsin 58 Zoraxel 58 anticancer compound 58 genotoxicity 58 AP# [003] 58 combinability 58 Protexia ® 58 IgG1 58 induces apoptosis 58 Tyrima 58 NEUMUNE 58 Exherin TM 58 2 methoxyestradiol 58 sigma receptors 58 antimitotic 58 Prodarsan ® 58 NOX E# 58 Homspera 58 alpha7 58 Anthim 58 Androxal TM 58 tkRNAi 58 sodium thiosulfate STS 58 phase 2a 58 favorable pharmacokinetic 58 Vaxfectin 58 receptor inhibitor 58 phase IIb clinical 58 potent antitumor 58 selective modulator 58 CD# monoclonal antibody 58 plasma kallikrein inhibitor 58 potent inhibitor 58 investigational pan BCR 58 Flt3 58 peptidomimetic 58 mediated inhibition 58 PDGFR 58 pomalidomide 58 CEQ# 58 Angiolix 58 Phase 2a clinical 58 Sphingomab TM 58 murine 58 ATL# [001] 58 Pharmacokinetic PK 58 anticancer agent 58 GRNCM1 58 nanomolar 58 cisplatin resistant 58 CCR2 58 HuMax CD# 58 HIF PHI 58 Anidulafungin 58 ara C 58 ZFP Therapeutic 58 synthase TS 58 siRNA conjugates 58 CaPre TM 58 Cloretazine ® 58 GelSite polymer 58 Ophena TM 58 CR# vcMMAE 58 PolyMedix defensin 58 antitumoral 58 Bendavia 58 ONCONASE R 58 PEGylated interferon 58 erlotinib Tarceva ® 58 Pentraxin 2 58 CCR5 antagonist 58 targeted antifolate 58 Omacetaxine mepesuccinate 58 potent anticancer 57 XmAb ® 57 trastuzumab DM1 T DM1 57 R roscovitine 57 enzastaurin 57 monoclonal 57 TÎ ² 4 57 infantile NCL 57 intranasal delivery 57 TKM ApoB 57 TKB# 57 LY# [003] 57 phase Ib 57 #nd EORTC NCI 57 selectively inhibits 57 metabolite identification 57 induce apoptosis 57 selective inhibition 57 entinostat 57 EndoTAG TM -1 57 Systemic Delivery 57 polymerase inhibitor 57 Onalta ™ 57 murine model 57 ANAVEX #-# [003] 57 cleavable linker 57 Lenocta 57 vitro 57 AQ4N 57 inhibited tumor 57 forodesine 57 cyclophilin inhibitor 57 flavopiridol 57 phosphate S1P 57 TB4 57 RNAi mediated 57 Hsp# inhibitor 57 Hsp# inhibitors 57 immunomodulatory 57 xenograft tumor models 57 Golimumab 57 Kevetrin 57 elacytarabine 57 IL #p# 57 Phase 2b Clinical Trial 57 LymphoStat B belimumab 57 SynCon ™ DNA 57 HDAC EGFR 57 Pharmacodynamic 57 ISIS # 57 Tie2 57 molecular determinants 57 humoral immune responses 57 transthyretin TTR mediated amyloidosis 57 Phase IIA 57 Phase 1b trial 57 PTP 1B 57 Immunogenicity 57 cyclophilin inhibitors 57 tubulin polymerization 57 Trodusquemine 57 pharmacokinetic characteristics 57 BiTE antibody 57 TPI ASM8 57 phase IIb study 57 humoral antibody 57 potent inhibitors 57 vivo preclinical studies 57 Aganocide ® 57 polyclonal 57 triphendiol 57 antagomirs 57 potent antiviral 57 Panzem 57 cationic lipid 57 cytoprotective 57 non nucleoside HCV 57 tolerability pharmacokinetics 57 RDEA# 57 preclinical toxicology 57 ALN PCS 57 next generation URAT1 57 Epratuzumab 57 teriflunomide 57 KSP inhibitor 57 DOS# 57 FK# 57 MGCD# [002] 57 mGluR2 NAM 57 vitro assay 57 CYC# 57 crizotinib PF # 57 PDE4 inhibitor 57 ceftazidime 57 vivo toxicology 57 kinase inhibitor 57 dose proportionality 57 Personalized Immunotherapy 57 PLX cells 57 intracellular uptake 57 OHR/AVR# 57 Pivotal Phase III 57 ImmunoVEX HSV2 57 systemic RNAi therapeutic 57 oxidative stress inducer 57 Phase #b/#a trial 57 atacicept 57 replicon 57 p# biomarkers 57 XL# XL# 57 OvaRex R 57 Anticalins ® 57 multicenter Phase II 57 oncolytic 57 mda 7 57 potency selectivity 57 Perifosine 57 eniluracil 57 multitargeted 57 cynomolgus monkeys 57 Cethromycin 57 Chemophase 57 signal transduction inhibitor 57 FOLOTYN ® 57 Annexin V 57 INCB# [002] 57 Antiviral Activity 57 matrix metalloproteases 57 GW# [003] 57 Curaxin 57 Overexpression 57 SNALP technology 57 telomerase inhibition 57 OMNARIS HFA 57 pharmacokinetic studies 57 isatoribine 57 oral picoplatin 57 nanomolar range 57 Novolimus 57 epithelial tumors 57 Afatinib 57 EZN 57 peripheral blood mononuclear 57 dacetuzumab 57 Vidofludimus 57 PI3K/Akt pathway inhibitor 57 LSI #P 57 histamine dihydrochloride 57 antibody responses 57 siRNA sequences 57 MET RET 57 vitro assays 57 phase IIa 57 anti EGFR antibody 57 CA9 SCAN 57 immunostaining 57 nucleotide analogs 57 TRANSFORMS 57 AVN# [001] 57 bortezomib Velcade 57 ToGA 57 immunohistochemical staining 57 volociximab 57 Lp PLA 2 57 oral antiviral 57 Tβ4 57 JAK2 inhibitors 57 Anticalins R 57 pertuzumab 57 MET amplification 56 PRLX # 56 constitutively expressed 56 Immunohistochemical staining 56 selective orally bioavailable 56 inhibit EGFR 56 drug GAP #B# 56 VEGFR2 56 Trofex TM 56 encapsulates siRNAs 56 Vaxfectin R formulated 56 Histone deacetylase 56 RNAi therapeutic targeting 56 EpCAM 56 proteasome inhibitors 56 glycosylation profile 56 Gleevec resistant 56 hA# 56 GPx 56 Seliciclib 56 NOD SCID mice 56 Squalamine 56 Phase 1b clinical 56 ulimorelin 56 OxBC 56 HCV polymerase 56 stated Michelle Berrey 56 Etoposide 56 Phase #b/#a clinical 56 lucinactant 56 V#F mutation 56 radiation sensitizer 56 Anticalins 56 RNAi Therapeutic 56 Janus Kinase 56 zanolimumab 56 humanized anti 56 Nanobody 56 LPA1 receptor 56 partial agonist 56 Nanobodies ® 56 NGX# 56 IMP# 56 IFN α 56 glucagon receptor 56 XL# [003] 56 Epothilones 56 torezolid phosphate 56 elotuzumab 56 PS# [001] 56 ATL/TV# 56 ICAAC 56 seliciclib 56 Elagolix 56 polymerase inhibitors 56 vaccine GRNVAC1 56 BrachySil TM 56 Phase 2b clinical trials 56 Aflibercept 56 ARRY # 56 SERMs 56 Trofex 56 Immunotherapeutic 56 investigational protease inhibitor 56 potent antiproliferative 56 TLE3 56 ARIKACE ™ 56 effector function 56 defensin mimetic antibiotic 56 humanized antibody 56 K RAS 56 orthotopic 56 Lodamin 56 GRN# 56 Atiprimod 56 Rigel R# 56 #T# L1 56 EGS# 56 IMGN# 56 TNFalpha 56 Inc. Nasdaq PPHM 56 ENMD 56 seliciclib CYC# 56 HepG2 cells 56 VNP#M 56 therapeutically relevant 56 KSP inhibitors 56 TRV# [001] 56 fibrotic disease 56 Tesetaxel 56 neratinib 56 Phase Ib 56 radiotherapeutic 56 TH# [003] 56 potent anti angiogenic 56 Fibroblast Growth Factor Receptor 56 Bezielle 56 Preclinical 56 poly ADP ribose polymerase 56 predictive biomarker 56 HuMax CD#b 56 antiangiogenesis 56 GeoVax vaccine 56 anti CD3 monoclonal 56 bexarotene 56 busulfan 56 LBH# 56 ritonavir boosted 56 transfection efficiency 56 CRMD# 56 ORAL Sync 56 Blinatumomab 56 RAV# 56 polyclonal antibody 56 ZK EPO 56 intratumoral injection 56 Th1 type 56 Preclinical Data 56 IND submission 56 JVRS 56 potent cytotoxic 56 PLK1 SNALP 56 hour bronchodilation 56 LT NS# 56 resolvin 56 Alocrest 56 TRX1 56 HCD# [002] 56 Anti Tumor 56 IgG4 56 pharmacodynamic parameters 56 Ramoplanin 56 inhibitor RG# 56 HCV polymerase inhibitors 56 siRNA mediated 56 immunomodulator 56 Imprime PGG 56 leading oral taxane 56 Locked Nucleic Acid LNA 56 Phase 2a 56 AEZS 56 investigational monoclonal antibody 56 HCV polymerase inhibitor 56 pharmacokinetic pharmacodynamic 56 darinaparsin ZIO 56 SynCon TM 56 HspE7 56 Hsp# inhibition 56 TriRima 56 riociguat 56 Tolerability 56 NexACT 56 small molecule tyrosine 56 mapatumumab 56 AEOL # 56 galiximab 56 plasma pharmacokinetics 56 velafermin 56 ORMD 56 inhibits VEGF 56 antiapoptotic 56 TRX# 56 TG# [001] 56 Phase IIb clinical trials 56 glucokinase activator 56 BiTE ® 56 Intravail R 56 Phase IIa trial 56 sodium glucose cotransporter 56 phenotyping 56 ARIKACE 56 Tarvacin Anti Viral 56 vivo imaging 56 oral FTY# 56 PD LID 56 pharmacokinetic PK profile 56 somatostatin 56 ZFP Therapeutic TM 56 HAAH 56 including eniluracil ADH 56 Annamycin 56 GAMMAGARD 56 talabostat 56 DB# [003] 56 EKC Cide 56 YONDELIS R 56 Nanobodies 56 ELACYT 56 epothilones 56 MGd 56 Cleviprex TM clevidipine 56 sapacitabine 56 Azedra ™ 56 Safinamide 56 pharmacokinetic 56 MAPK pathway 56 targeted radiotherapeutic 56 HE# [002] 56 predictive toxicology 56 lenalidomide Revlimid R 56 XL# anticancer compounds 55 small molecule agonists 55 Kinoid 55 potent suppressor 55 mimetics 55 PDX pralatrexate 55 MAGE A3 ASCI 55 Angiocept 55 prucalopride 55 tipifarnib 55 pharmacokinetic equivalence 55 menadione 55 AMPK activators 55 antitumor effect 55 molecular biomarkers 55 antimetastatic activity 55 ZYBRESTAT fosbretabulin 55 GelSite R polymer 55 systemic siRNA 55 ATL# [002] 55 histone deacetylase HDAC 55 anticancer therapeutics 55 xenografts 55 epigenetic therapies 55 Haptoglobin 55 Panzem R NCD 55 tumor antigen 55 Rebif ® 55 rHuPH# 55 VEGF receptor 55 retaspimycin 55 HCV replicon 55 antisense compounds 55 alpha antagonist 55 antibody MAb 55 p# biomarker 55 Solorel TM 55 pharmacokinetic profile 55 #th Interscience Conference 55 HCV NS5B polymerase 55 pro apoptotic 55 posaconazole 55 biased ligand 55 MT#/MEDI-# 55 potent antibacterial 55 systemic RNAi 55 Vitaxin 55 beta Estradiol 55 anti CD# antibodies 55 confirmatory clinical 55 HIF PH inhibitors 55 deforolimus 55 dasatinib Sprycel 55 leukemia AML 55 AMD# [003] 55 effector functions 55 nanopharmaceutical 55 FasL 55 antibody blinatumomab MT#/MEDI-# 55 DDP# 55 dose cohort 55 Epidermal Growth Factor Receptor 55 MT# MEDI 55 erythropoietic 55 perifosine KRX 55 microRNA miR 55 nitazoxanide 55 orally dosed 55 ProLindac 55 hypoxia activated prodrug 55 GelVac TM 55 trastuzumab DM1 55 JAK2 55 romidepsin 55 thymidylate synthase TS 55 inhaled iloprost 55 immunotoxin 55 prophylactic vaccine 55 induced tumor regression 55 pharmacodynamic endpoints 55 Tezampanel 55 Palifosfamide 55 Phase IIa 55 kinase profiling 55 oritavancin 55 peptide antigens 55 pharmacodynamic effects 55 inhibit metastasis 55 RRM1 55 alagebrium 55 FLT3 55 bortezomib Velcade ® 55 velafermin belinostat 55 Capesaris 55 lintuzumab SGN 55 Synavive 55 YONDELIS 55 intranasal formulation 55 metabolomic profiling 55 Iloperidone 55 annexin 55 Phase IIIb clinical 55 BiTE R 55 cobiprostone 55 Onalta 55 silico prediction 55 HuMax CD4 55 PEGylated 55 situ hybridization 55 Tarvacin 55 brentuximab vedotin SGN 55 XL# SAR# 55 PROCHYMAL 55 Xenograft 55 MAbs targeting 55 EDEMA3 trial 55 novel peptides 55 IND enabling 55 oral anticancer 55 tanespimycin 55 JAK3 55 Quinamed 55 PROSTVAC VF 55 LNP formulations 55 BioVant 55 cetuximab Erbitux ® 55 Aurexis 55 microtubule inhibitor 55 Zemiva TM 55 LB# [003] 55 systemic absorption 55 somatostatin analogue 55 PI3K Akt 55 CD# antibody [001] 55 DR Cysteamine 55 alkylating agent 55 Antigenics QS 55 GFT# 55 caspofungin 55 PANVAC VF 55 preclinical pharmacokinetic 55 Kevetrin ™ 55 immunofluorescence staining 55 pleiotropic 55 IL 1ß 55 Cannabinor 55 immunoregulatory 55 cetuximab Erbitux R 55 Immunohistochemical analysis 55 GHRH 55 trastuzumab Herceptin R 55 Parkinson disease levodopa induced 55 EOquin TM 55 nitric oxide donating prostaglandin 55 interferon IFN 55 SparVax ™ 55 Posiphen 55 adipogenic 55 immunized mice 55 Solazed 55 TLR9 55 calcitonin 55 VLP vaccine 55 selective antagonist 55 EGFr 55 Telatinib 55 therapeutic monoclonal antibodies 55 CIMZIA TM 55 administered intranasally 55 mdx mouse 55 Aplidin R 55 Clinical Trial Results 55 torsemide ER 55 serum antibody 55 dasatinib Sprycel ® 55 siRNA therapeutics 55 masitinib 55 Dapagliflozin 55 carcinogenicity study 55 cellular uptake 55 PI3K delta 55 synthetic peptides 55 nanoviricide drug 55 PF # [001] 55 antibody MT# 55 Inc. Nasdaq IMGN